Citius Oncology, Inc. Deferred Costs, Noncurrent
Citius Oncology, Inc. (CTOR) had Deferred Costs, Noncurrent of $169.25 thousand as of 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Balance Sheet › Assets
us-gaap:DeferredCosts · last filed 2026-05-15
- 2026-03-31: Deferred Costs, Noncurrent $169.25K.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2026-03-31 | $169.25K 10-Q · filed 2026-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |